Meeting
2019 ASCO Annual Meeting
Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer.
Authors
Prashanth Reddy Moku
Penn State Hershey College of Medicine, Hershey, PA
Prashanth Reddy Moku , Lois E. Shepherd , Suhail Ali , Kim Leitzel , Wendy R. Parulekar , Liting Zhu , Shakeel Virk , Dora Nomikos , Samuel Aparicio , Karen A. Gelmon , Joseph Drabick , Leah Cream , Scott Halstead , Hyma Vani Polimera , Ashok Maddukuri , Aamnah Ali , Joyson Poulose , Howard Spiegel , Bingshu E. Chen , Allan Lipton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1031)
DOI
10.1200/JCO.2019.37.15_suppl.1031
Abstract #
1031
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Serum PD-L1 and outcomes in CCTG MA.31 phase 3 trial of anti-HER2 therapy in first-line HER2+ metastatic breast cancer patients (trastuzumab arm only).
First Author: Kim Leitzel
Poster
2018 ASCO Annual Meeting
![A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].](https://d201v5jt9ylckg.cloudfront.net/214/12940/161815/161815_poster_pv.jpg)
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
First Author: Stephen K. L. Chia
Poster
2016 ASCO Annual Meeting
KEYNOTE-181: phase 3, open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma.
First Author: Toshihiko Doi
Poster
2015 ASCO Annual Meeting
Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).
First Author: Ahmad Awada